Claims for Patent: 9,676,833
✉ Email this page to a colleague
Summary for Patent: 9,676,833
Title: | Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof |
Abstract: | Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described. |
Inventor(s): | Roschke; Viktor (Bethesda, MD), Lafleur; David (Washington, DC), Hilbert; David M. (Bethesda, MD), Kiener; Peter (Potomac, MD) |
Assignee: | Zyngenia, Inc. (Washington, DC) |
Application Number: | 14/527,656 |
Patent Claims: | 1. A complex comprising a modular recognition domain (MRD) capable of binding angiopoietin-2 (ANG-2), wherein the MRD comprises amino acid sequence
AQTNFMPMDQEEALLYEEFI (SEQ ID NO:108) or amino acid sequence AQTNFMPMDQDEALLYEEFI (SEQ ID NO:109).
2. The complex of claim 1, wherein the MRD is fused to a heterologous protein. 3. The complex of claim 1, which further comprises an antibody. 4. The complex of claim 3, wherein the MRD and the antibody are covalently bound. 5. The complex of claim 4, wherein the antibody binds ANG-2. 6. The complex of claim 4, wherein the MRD and the antibody bind different targets. 7. The complex of claim 6, wherein the antibody binds a target selected from: vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), type 1 insulin-like growth factor 1 (IGF1), fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3), vascular endothelial growth factor receptor 1 (VEGFR1), epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), erb b2 receptor tyrosine kinase 2 (ErbB2), erb b2 receptor tyrosine kinase 3 (ErbB3), type 1 insulin-like growth factor 1 receptor (IGF1R), hepatocyte growth factor receptor (cMET), cluster of differentiation 19 (CD19), and cluster of differentiation 20 (CD20). 8. The complex of claim 7, wherein the antibody competitively inhibits: (a) binding of trastuzumab to ErbB2; (b) binding of pertuzumab to ErbB2; (c) binding of bevacizumab to VEGF; (d) binding of cetuximab to EGFR; (e) binding of panitumumab to EGFR; (f) binding of zalutumumab to EGFR; (g) binding of nimotuzumab to EGFR; (h) binding of matuzumab to EGFR; (i) binding of figitumumab to IGF1R; (j) binding of AMG 479 to IGF1R; (k) binding of cixutumumab to IGF1R; (l) binding of dalotuzumab to IGF1; (m) binding of BIIB022 to IGF1; or (n) binding of MEDI-573 to IGF1. 9. The complex of claim 6, wherein the antibody binds a target selected from: interferon-alpha, interferon alpha receptor, interferon beta, interferon beta receptor, interferon-gamma, sphingosine 1 phosphate receptor (S1PR), integrin avb3, Interleukin-1B (IL-1B), Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin 4 Receptor (IL-4R), Interleukin-5 (IL-5), Interleukin-5 Receptor (IL-5R), Interleukin-6 (IL-6), Interleukin 6-Receptor (IL-6R), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-9 (IL-9), Interleukin-9 Receptor (IL-9R), Interleukin-10 Receptor (IL-10R), Interleukin-11 (IL-11), Interleukin-12 (IL-12), Interleukin-13 (IL-13), Interleukin-23 (IL-23), Interleukin-15 (IL-15), Interleukin-18 (IL-18), Interleukin-21 (IL-21), Inducible T-cell COStimulator (ICOS), programmed cell death protein-1 (PD-1), and Leukemia Inhibitory Factor (LIF). 10. The complex of claim 6, wherein the antibody binds to tumor necrosis factor alpha (TNF). 11. The complex of claim 10, wherein the antibody competitively inhibits binding of adalimumab, golumimab, or infliximab to TNF. 12. A pharmaceutical composition comprising the complex of claim 3. |
Details for Patent 9,676,833
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.